Table 1.
Patient Characteristics
| Characteristic | RFA | SBRT | P |
|---|---|---|---|
| No. of patients | 161 | 63 | — |
| No. of lesions | 249 | 83 | — |
| No. of lesions treated per patient | .13 | ||
| Median | 1 | 1 | |
| Range | 1-6 | 1-4 | |
| No. of lesions treated per patient | .14 | ||
| 1 | 109 | 49 | |
| 2 | 33 | 9 | |
| > 2 | 19 | 5 | |
| Age, years | .09 | ||
| Median | 60 | 62 | |
| Range | 31-81 | 35-85 | |
| Sex, male | 117 (72.7) | 54 (85.7) | .04 |
| Race | .18 | ||
| White | 132 (82.0) | 36 (57.1) | |
| African American | 14 (8.7) | 2 (3.2) | |
| Asian | 7 (4.3) | 1 (1.6) | |
| Other/unknown | 8 (5.0) | 24 (38.1) | |
| Liver transplant | 34 (21.1) | 4 (6.3) | .01 |
| Type of RFA | — | ||
| Percutaneous | 242 (97.2) | — | |
| Intraoperative | 7 (2.8) | — | |
| Use of fiducials in SBRT | — | ||
| Yes | — | 21 (25.3) | |
| No | — | 62 (74.7) | |
| Cirrhosis | 238 (95.6) | 65 (78.3) | < .001 |
| Liver disease | .14 | ||
| Hepatitis B | 24 (9.6) | 3 (3.6) | |
| Hepatitis C | 149 (59.8) | 44 (53.0) | |
| Alcoholic cirrhosis | 21 (8.4) | 10 (12.0) | |
| NAFLD | 13 (5.2) | 1 (1.2) | |
| Other | 21 (8.4) | 3 (3.6) | |
| Child-Pugh score | .003 | ||
| Mean | 6.9 | 6.2 | |
| Child-Pugh score | .003 | ||
| A | 121 (49.6) | 57 (68.7) | |
| 5 | 78 (32.0) | 35 (42.2) | |
| 6 | 43 (17.6) | 22 (26.5) | |
| B | 103 (42.2) | 24 (28.9) | |
| 7 | 32 (13.1) | 9 (10.8) | |
| 8 | 40 (16.4) | 11 (13.3) | |
| 9 | 31 (12.7) | 4 (4.8) | |
| C | 20 (8.2) | 2 (2.4) | |
| 10 | 12 (4.9) | 2 (2.4) | |
| 11 | 4 (1.6) | — | |
| 12 | 3 (1.2) | — | |
| 14 | 1 (0.4) | — | |
| AFP | .04 | ||
| Median | 8.8 | 18.6 | |
| Range | 1.4-42,630.0 | 1.4-6,256.0 | |
| Platelet counts | .62 | ||
| Median | 92 | 97 | |
| Range | 25-505 | 19-293 | |
| No. of prior liver-directed therapies | < .001 | ||
| Median | 0 | 2 | |
| Range | 0-7 | 0-7 | |
| Tumor diameter, maximum, cm | .14 | ||
| Median | 1.8 | 2.2 | |
| Range | 0.6-7.0 | 0-10.0 | |
| Tumor diameter, maximum, cm | .21 | ||
| < 2 cm | 137 (55.0) | 39 (47.6) | |
| ≥ 2 cm, < 3 cm | 57 (22.9) | 21 (25.6) | |
| ≥ 3 cm, < 5 cm | 52 (20.9) | 19 (23.2) | |
| ≥ 5 cm | 3 (1.2) | 3 (3.7) | |
| T stage | .32 | ||
| T1 | 123 (49.8) | 38 (45.8) | |
| T2 | 121 (49.0) | 40 (48.2) | |
| T3a | 3 (1.2) | — | |
| T3b | — | 5 (6.0) | |
| Follow-up for all patients, months | .01 | ||
| Median | 20.0 | 13.0 | |
| Range | 0-112.8 | 0.5-86.5 | |
| Follow-up for living patients, months | .001 | ||
| Median | 50.9 | 27.0 | |
| Range | 3.5-112.8 | 0.5-86.5 |
NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviations: AFP, alpha-fetoprotein; NAFLD, nonalcoholic fatty liver disease; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy.